[
    [
        {
            "time": "2019-06-26",
            "original_text": "AbbVie Rebounds as Market Warms to Allergan Deal, Botox Potential",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Allergan",
                    "Botox",
                    "Deal"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie Rebounds as Market Warms to Allergan Deal, Botox Potential",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-06-26",
            "original_text": "AbbVie Is 'The New Cash King' As It Takes On Botox-Maker Allergan",
            "features": {
                "keywords": [
                    "Cash King",
                    "Botox",
                    "Allergan"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie Is 'The New Cash King' As It Takes On Botox-Maker Allergan",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-06-26",
            "original_text": "AbbVie to Buy Allergan: Prescribed ETFs",
            "features": {
                "keywords": [
                    "Buy",
                    "Allergan",
                    "ETFs"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals",
                    "ETFs"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie to Buy Allergan: Prescribed ETFs",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-06-26",
            "original_text": "AbbVie to Acquire Allergan in Nearly $62B Cash & Stock Deal",
            "features": {
                "keywords": [
                    "Acquire",
                    "Allergan",
                    "$62B"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie to Acquire Allergan in Nearly $62B Cash & Stock Deal",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 10,
                "Impact": 10,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        },
        {
            "time": "2019-06-26",
            "original_text": "Here's Why Nobody's Happy About This $63 Billion Buyout",
            "features": {
                "keywords": [
                    "$63 Billion",
                    "Buyout",
                    "Unhappy"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Here's Why Nobody's Happy About This $63 Billion Buyout",
                "Correlation": 8,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-06-26",
            "original_text": "Big Pharma Has to Bet Big on M&A. Investors Don’t.",
            "features": {
                "keywords": [
                    "Big Pharma",
                    "M&A",
                    "Investors"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Big Pharma Has to Bet Big on M&A. Investors Don’t.",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-06-26",
            "original_text": "Health Care Sector Update for 06/26/2019: ACST, ABBV, EYEG, NBRV, AGN, JNJ, PFE, ABT, MRK, AMGN",
            "features": {
                "keywords": [
                    "Health Care",
                    "Sector Update",
                    "ACST",
                    "ABBV",
                    "AGN"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "health care"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Health Care Sector Update for 06/26/2019: ACST, ABBV, EYEG, NBRV, AGN, JNJ, PFE, ABT, MRK, AMGN",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 10,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        }
    ]
]